According to the Zhitong Finance App, Hendi Pharmaceutical (301211.SZ) released its report for the third quarter of 2026. In the first three quarters, the company achieved revenue of 354 million yuan, an increase of 11.14% over the previous year. Net profit attributable to shareholders of listed companies was 396.57,800 yuan, an increase of 89.45% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 14.3774 million yuan, an increase of 2543.79% over the previous year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.